Other Vaccines - Malta

Malta

Highlights

The projected revenue for the Other Vaccines market in Malta is expected to reach US$7.50m in 2024.
This forecast indicates a positive growth trend with an annual growth rate (CAGR 2024-2029) of 11.15%, resulting in a market volume of US$12.73m by 2029.
When compared globally, it is noteworthy that United States is anticipated to generate the highest revenue in the Other Vaccines market, reaching US$24.73bn in 2024.
The demand for other vaccines in Malta has increased significantly due to the government's proactive approach towards public health.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Malta has been experiencing steady growth over the past few years.

Customer preferences: Malta has a highly developed healthcare system and the population has a strong awareness of the importance of preventative healthcare. This has led to an increasing demand for vaccines, including those outside the standard childhood immunization schedule.

Trends in the market: There has been a growing trend towards travel vaccines, as Malta is a popular tourist destination and many Maltese residents travel abroad frequently. Additionally, there has been an increasing demand for vaccines to protect against diseases such as shingles and meningitis. This is likely due to the aging population in Malta, as these diseases are more common in older adults.

Local special circumstances: One factor that has contributed to the growth of the Other Vaccines market in Malta is the country's small size. With a population of just over 500,000 people, there is a relatively small market for healthcare products and services. However, this also means that the market is highly concentrated, with a few key players dominating the industry.

Underlying macroeconomic factors: Malta has a strong economy, with a high GDP per capita and low unemployment rate. This has led to increased spending on healthcare, including preventative measures such as vaccines. Additionally, the Maltese government has made a concerted effort to promote public health, which has further supported the growth of the Other Vaccines market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.